Physician profile
Bruce Walker
NPI 1790717486
$4,037.59
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,200 · 2020: $590 · 2021: $1,083 · 2022: $761 · 2023: $287 · 2024: $117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $341 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $62.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $341.46 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $62.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $970.33 | 2019-2023 | Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $520.85 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $396.83 | 2019-2023 | Entyvio |
| Janssen Biotech, INC. | $286.60 | 2019-2023 | Simponi Aria, Remicade, Stelara |
| Gilead Sciences, INC. | $228.41 | 2019-2023 | |
| Allergan, INC. | $217.50 | 2020 | |
| Pfizer INC. | $177.65 | 2019-2021 | |
| Celgene Corporation | $166.49 | 2021-2022 | |
| Covidien Lp | $143.14 | 2019 | |
| Braintree Laboratories, INC. | $128.93 | 2019-2022 | |
| Lilly USA, LLC | $117.37 | 2024 | Omvoh |
| E.R. Squibb & Sons, L.L.C. | $114.53 | 2021 | |
| Ucb, INC. | $87.15 | 2019 | |
| Aimmune Therapeutics, INC. | $62.50 | 2023 | |
| Qol Medical, LLC | $56.79 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $54.49 | 2023 | Gi Genius |
| Shionogi INC | $52.83 | 2019 | |
| Redhill Biopharma INC. | $31.55 | 2021 | |
| Nestle Healthcare Nutrition INC. | $31.40 | 2022 | |
| Intercept Pharmaceuticals, INC. | $29.39 | 2023 | Ocaliva |
| Merck Sharp & Dohme LLC | $26.51 | 2019-2021 | |
| Ardelyx, INC. | $25.06 | 2022 | |
| Olympus America INC. | $20.85 | 2021 | |
| Daiichi Sankyo INC. | $19.56 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $17.63 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $15.42 | 2020 | |
| Genzyme Corporation | $13.82 | 2022 | |
| Organon LLC | $13.02 | 2021 | |
| Alexion Pharmaceuticals, INC. | $10.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.